111
Participants
Start Date
January 31, 2007
Primary Completion Date
November 30, 2010
Study Completion Date
February 28, 2011
Mapatumumab
30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
Mapatumumab
10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
Paclitaxel
200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
Carboplatin
AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
Fővárosi Önkormányzat Uzsoki Utcai Kórház, Budapest
Országos Korányi TBC és Pulmonológiai Intezet, Budapest
Debrecen University, Medical and Health Center, Dept of Oncology, Debrecen
Kenézy Gyula Kórház, Debrecen, Pulmonológia, Debrecen
Charite - Campus Mitte, Universitätsmedizin Berlin, Abteilung Onkologie und Hämatologie, Berlin
Universitätsmedizin Berlin, Centrum für Innere Medizin, Berlin
Chevy Chase Health Care, Chevy Chase
University of Maryland, Greenebaum Cancer Center, Baltimore
Fairfax-Northern Virginia Hematology Oncology, PC, Fairfax
Krankenhaus Großhansdorf, Großhansdorf
Pius-Hospital, Oldenburg
Medical University of South Carolina: Hollings Cancer Center, Charleston
Palm Beach Cancer Institute, West Palm Beach
Osceola Cancer Center, Kissimmee
Birmingham Hematology and Oncology Associates, LLC, Birmingham
The Sarah Cannon Cancer Center, Nashville
Universitätsklinik Magdeburg, Klinik für Kardiologie, Angiologie und Pneumologie, Magdeburg
Kentuckiana Cancer Institute, PLLC, Louisville
Paracelsus Klinik, Zentrum für Tumordiagnostik und -therapie, Osnabrück
Klinikum der Johannes-Gutenberg-Universität Mainz, Mainz
Orchard Research, LLC, Skokie
LaGrange Oncology Associates, LaGrange
Rush University Medical Center, Chicago
Universitätsklinikum Mannheim, Chirurgische Klinik, Mannheim
UT Health Science Center at San Antonio, Be Well Center, San Antonio
University of Colorado Health Sciences Center, Aurora
Asklepios Fachkliniken München-Gauting, Gauting
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage
Institutul Oncologic 'Prof . Dr. I. Chiricuta' Cluj-Napoca, Cluj-Napoca
Spitalul Clinic Judetean Oradea, Oncology Department, Oradea
Hackensack University Medical Center, Hackensack
Krankenhaus Martha-Maria Halle-Dölau, Halle
Institutul Oncologic 'Prof Dr. Al Trestioreanu' Bucuresti, Bucharest
Lead Sponsor
Human Genome Sciences Inc.
INDUSTRY